It looks like the first part of the University of Washington study of patients with severe heart failure taking 2,000 mg of NR for 12 weeks has been published. Presumably, there will be a second publication soon that reveals if the 19 heart patients saw an improvement in their heart’s ejection fractions (EF). Highlights from the press release and the study:
“In this study we aimed to investigate the mechanistic link between mitochondrial dysfunction and inflammatory activation in peripheral blood mononuclear cells (PBMCs), and the potential anti-inflammatory effect of boosting N.A.D.+ level.
“PBMCs have been implicated in the inflammatory response that leads to the decompensation and worsening of heart failure. Mitochondrial health of PBMCs, as evidenced by the respiration rate, could be the culprit and reporter of the inflammatory process.
“By increasing the mitochondrial health of PBMCs, proinflammatory cytokine production was reduced. These findings further support an important role NR may have in a variety of cardiovascular-related health declines.”
“We found that increasing N.A.D+ levels with nicotinamide riboside (NR) suppressed inflammatory activation in end-stage heart failure patients,”
https://finance.yahoo.com/news/pilot-study-indicates-niagen-may-103200595.html
The Whims of Change 